User Name Password Remember Me  
 
 
   
Video Podcast
Audio Cast
Mobile(WAP)
  Pedi Poll  
Should reservation for backward classes be enforced in post graduate medical education?
Yes
No
  Translate This Page  
 
CONGENITAL MALARIA WITH APARASITEMIA ON PERIPHERAL SMEAR
Dr Ira Shah
MD, DCH (Gold Medalist), FCPS, DNB

Case Report


A one and a half month old male child presented with fever (upto 102oF) and abdominal distension since 15 days of life. Antenatally, his mother had vivax malaria at 6 months of gestation for which she was treated with chloroquine. Birth history was normal with birth weight being 2.3 kg. On examination, the child had severe pallor with heart rate of 130/minute. There was no edema. He had firm hepato-splenomegaly (liver span being 7 cms) without dysmorphic features. His weight gain was appropriate for his age and other systemic examination was normal. A differential diagnosis of congenital malaria, sepsis and congenital leukemia was considered. His hemoglobin was 5.2 gm% with white cell count being 9,000/cumm, Reticulocyte count of 3.5% and platelet count of 1,70,000/cumm. Peripheral smear did not show any malarial parasites or abnormal cells.His CRP and blood culture were negative. USG skull did not show any intracranial calcifications. His HIV ELISA was negative.

Thus sepsis, intrauterine infections such as CMV, HIV, Toxoplasma and leukemia seemed unlikely. His liver enzymes were slightly deranged with SGOT of 62 IU/dl [Normal = 0 to 25 IU/dl] and SGPT of 81 IU/dl (Normal = 0 to 46 IU/dl]. In view of suspicion of congenital malaria, an OptiMAL test for P. falciparum & P. vivax was done, which was positive for P. vivax. The child was treated with chloroquine in initial dose of 10 mg/kg base followed by 5 mg/kg at 6, 24, 48 hours after 1st dose and started on hematinics. His fever subsided and repeat optimal test after 72 hours of therapy was negative. His hemoglobin was 5.9 gm% after 1 week of hematinics and reticulocyte count was 3.9% with normal liver enzymes. Thus a diagnosis of congenital malaria was established inspite of a negative peripheral smear for P.vivax but on basis of a positive OptiMAL test for P. vivax, which subsequently became negative following therapy.

Discussion


In areas in which malaria is endemic, infants are exposed to mosquitoes at a very young age and may become infected making it difficult to distinguish between acquired and congenital cases. Studies have shown that though placenta may be frequently infected in pregnant mothers with malaria, it still serves as an effective barrier and prevents the parasites from reaching the fetus most of the times. Thus clinically apparent congenital infections are rare and rate is 1-4%. Congenital malaria is more common in mothers who have acute attacks of malaria in pregnancy than in those with sub clinical infections. Clinical onset of disease in a congenitally infected infant can be delayed for weeks and rarely for months. It is probable that IgG antibody transplacentally acquired from the mother is an important factor to determine whether parasites reaching the fetal circulation cause infection or not and may also lengthen the incubation period. Usually onset of symptom is between 10 to 28 days of age with a range from 14 hours of life to 8 weeks of age. Commonest clinical findings are fever, anemia and splenomegaly. Jaundice, hepatomegaly, FTT and sepsis may also be present. Laboratory studies may demonstrate malaria parasite (P. falciparum, P. vivax and P. malarial are all known to cause congenital infections) with anemia and reticulocytosis. Thus clinical picture may not vary in congenital on acquired malaria.

Treatment


Chloroquine is the drug of choice in initial dose of 10 mg/kg base followed by 5 mg/kg at 6, 24, 48 hours after 1st dose. Administration of primaquine is not necessary as no exoerythrocytic phase is seen in congenital infections. In patients with chloroquine resistant strains of P. falciparum, quinine and trimethoprim sulfamethoxazole may be used.

Prevention


Chloroquine is the drug of choice in initial dose of 10 mg/kg base followed by 5 mg/kg at 6, 24, 48 hours after 1st dose. Administration of primaquine is not necessary as no exoerythrocytic phase is seen in congenital infections. In patients with chloroquine resistant strains of P. falciparum, quinine and trimethoprim sulfamethoxazole may be used.

References


  1. Palmer CJ, Bonilla JA, Bruckner DA, Barnett ED, Miller NS, Haseeb MA, Masci JR, Stauffer WM – Multicentric study to evaluate the OptiMAL test for rapid diagnosis of malaria in US hospitals. J Clin Microbiol. 2003 Nov;41(11):5178-82.

  2. The hospital- and the field- based performances of the OptiMAL for malaria diagnosis and treatment monitoring in Central India – Singh N, Valecha N, Nagpal AC, Mishra SS, Varma HS, Subbarao SK. Ann Trop Med Parasitol. 2003 Jan;97(1):5-13.
Last Updated on 01-02-2005

How to cite this url

Shah I.Congenital Malaria With Aparasitemia On Peripheral Smear.Pediatric Oncall [serial online] 2005 [cited 2005 January 1];2. Available from:
http://www.pediatriconcall.com/fordoctor/casereports/congenital_malaria.asp
 
  Grants  
 » Apply For Research Grant
  Search  
Hospitals
Pediatrician
Special Schools
Medical Colleges
Pediatric Conferences
Jobs & Vacancies
Journals
NGO's
  Ped Tools  
Pediatric Calculator
Drug Index
Medical Equipment
Vaccine Reminder
Adverse Drug Reactions
Biochemical Profile
Online MCQ's
  Calculators  
+ Growth
+ Conversion
+ Renal
+ Pregnancy
+ Blood Pressure
+ Blood Group
+ Critical Care
+ Drug Dose
+ Diarrhea Solution
+ Reference Values
+ Antibody Test
 
 
Parent Corner l Kids Corner l Terms & Condition l Advertising l Feedback l Awards
About Us
l Link to Us l Site Map l Shopping Mall  
Partner Sites
 HIV in Children  Infection in Children  Pedcall  Medical ADRIS  Vaccine Reminder  Pediatric Oncall Journal

Copyright© 2000-2007 All rights reserved with Levioza

Disclaimer:The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitue an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.

 
Sitemap For Doctor | Sitemap For Parent | Sitemap For Kids Site designed and maintained by Levioza